If you or someone close to you are suffering from non-small cell lung cancer, Lumakras can provide some much-needed hope. Especially in cases where first-line treatments such as chemotherapy or immunotherapy have proven inefficient.
Here, you'll find all you need to know about this promising second-line treatment inhibitor of the KRAS G12-Mutant NSCLC.
What is NSCLC?
There are two forms of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Observed under a microscope, NSCLC's cancer cells are larger than those of SCLC. That’s how it got its name.
NSCLC is the most common kind of lung cancer, affecting over 230,000 people each year, in the USA alone. NSCLC tends to progress more slowly than other lung cancers. Around 40% of patients are diagnosed after the cancer has spread to other body parts[2].
What is Lumakras?
Lumakras (sotorasib) is a
